missing translation for 'onlineSavingsMsg'
Learn More
Learn More
This item is not returnable.
View return policy
Description
The EH12.1 monoclonal antibody specifically binds to CD279. CD279 is an immunoregulatory receptor that is expressed on activated T cells, B cells and myeloid cells and contains an immunoreceptor tyrosine-based inhibitory motif (ITIM) in the cytoplasmic region. Mice deficient in CD279 show a breakdown of peripheral tolerance and manifest multiple autoimmune symptoms. PD-L1 and PD-L2 are ligands of CD279 and are members of the B7 gene family. Interaction of CD279:PD-Ligands results in inhibition of T cell proliferation and cytokine secretion. Reports suggest that the B7/CTLA-4 pathway functions primarily to attenuate, limit, and/or terminate naοve T-cell activation in secondary lymphoid organs. The PD-ligand:CD279 pathway, on the other hand, may primarily attenuate, limit, and/or terminate T-, B-, and myeloid cell activation/effector function at sites of inflammation in the periphery.
The antibody was conjugated to BD Horizon™ BV421 which is part of the BD Horizon™ Brilliant Violet™ family of dyes. With an Ex Max of 407-nm and Em Max at 421-nm, BD Horizon™ BV421can be excited by the violet laser and detected in the standard Pacific Blue™ filter set (eg, 450/50-nm filter). BD Horizon™ BV421conjugates are very bright, often exhibiting a 10 fold improvement in brightness compared to Pacific Blue™ conjugates.
Specifications
| CD279 | |
| Monoclonal | |
| Brilliant Violet 421 | |
| Aqueous buffered solution containing BSA and ≤0.09% sodium azide. | |
| Human PD-1 Recombinant Protein | |
| 50 Tests | |
| Primary | |
| Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. |
| Flow Cytometry | |
| EH12.1 | |
| hPD-1; PD1; PDCD1; Programmed cell death 1; SLEB2 | |
| Mouse | |
| Affinity Purified | |
| RUO | |
| Human | |
| IgG1 κ |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction